Search Results

Renovaro Biosciences Inc. announced today the results of the Company’s Special Meeting of Shareholders held at 12:00 pm ET on January 25, 2024.

Renovaro Inc. announced that it completed its acquisition of GEDi Cube Intl Ltd. Renovaro, which means renew, combines the power of the AI Health Tech platform of GEDiCube with the advanced cell and gene-therapy Biotech platform of Renovaro Biosciences to accelerate precision, personalized medicine, and a new era in healthcare innovation.

Renovaro Inc. and the Amsterdam UMC Cancer Center announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy.

Renovaro Biosciences Inc. is pleased to announce the appointment of Leni Boeren and Ruud Hendriks as Independent Directors.

Renovaro Inc., a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board.

Renovaro Biosciences Inc., a biotechnology corporation focusing on cell, gene, and immunotherapy, has announced that Avram Miller will join its Board of Directors.

Renovaro Biosciences Inc., an advanced, preclinical biotechnology firm in cell, gene and immunotherapy has signed a definitive agreement to combine with GEDi Cube Intl Ltd., an AI medical technology company, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition.

Renovaro BioSciences congratulates GEDi Cube on its appointment of Dr. Lester Russell as Chief Medical Officer.

Renovaro Inc. and Cyclomics proudly announce a significant milestone in their collaboration.